GLPwatch
Papers (12034)
Page 144 of 201, ranked by citation count.
- Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.
- Efficacy and safety of exenatide once weekly: an overview of the DURATION trials.
- Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV.
- Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.
- Data-driven prioritization of high-risk individuals for weight loss interventions.
- Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.
- Liraglutide and systolic blood pressure.
- New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.
- Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
- Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.
- Atherosclerotic features in patients with heart failure.
- Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes.
- Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy).
- Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click Chemistry-Modifiable Position 26.
- Effects of exenatide in a morbidly obese patient with type 2 diabetes.
- Insulins for type 2 diabetes.
- Hot Water Eliminates the Bitter Taste of Oral Semaglutide: A Report of Four Cases.
- Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence.
- Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity.
- Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks.
- Effects of different hypoglycaemic drugs on beta-cell function in type 2 diabetes mellitus: a systematic review and network meta-analysis.
- The Obesity Drug Revolution: New Frontiers in Pharmacotherapy.
- Rhabdomyolysis triggered by initiation of tirzepatide.
- Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study.
- The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
- Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.
- Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
- Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
- Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
- Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment.
- Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.
- The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice.
- Semaglutide (Ozempic) for weight loss.
- Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection.
- Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
- Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice.
- Pharmacologic options for the treatment of overweight and obesity.
- Exenatide once weekly: opportunities in the primary care setting.
- Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway.
- The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care.
- Semaglutide in the Real World: Attitudes of the Population.
- Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States.
- Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.
- Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss.
- Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.
- Structural stability-chromatographic retention relationship on exenatide diastereomer separation.
- Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.
- Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study.
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- The mechanism of glucagon-like peptide-1 participation in the osmotic homeostasis.
- Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.
- The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance.
- Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF).
- Fatal, Fulminant, Necrotizing Pancreatitis Associated With Recent Tirzepatide Initiation.
- Semaglutide exposures reported to the NSW Poisons Information Centre: effects of social media marketing and supply chain disruptions.
- Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.
- Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.
- Exendin-4 effects on islet volume and number in the mouse pancreas.
- Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
- Production of Fc-fused receptor agonists for glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) in the milk of transgenic mice.